Results 21 to 30 of about 66,449 (275)

Diagnostic Microdosing Approach to Study Gemcitabine Resistance [PDF]

Chemical Research in Toxicology, 2016
Gemcitabine metabolites cause the termination of DNA replication and induction of apoptosis. We determined whether subtherapeutic "microdoses" of gemcitabine are incorporated into DNA at levels that correlate to drug cytotoxicity. A pair of nearly isogenic bladder cancer cell lines differing in resistance to several chemotherapy drugs were treated with
Scharadin, Tiffany M, Zhang, Hongyong, Zimmermann, Maike, Wang, Sisi, Malfatti, Michael A, Cimino, George D, Turteltaub, Kenneth, de Vere White, Ralph, Pan, Chong-xian, Henderson, Paul T   +9 more
openaire   +4 more sources

Long non-coding RNA LINC00665 promotes gemcitabine resistance of Cholangiocarcinoma cells via regulating EMT and stemness properties through miR-424-5p/BCL9L axis

Cell Death and Disease, 2021
Gemcitabine is the first-line chemotherapy drug for cholangiocarcinoma (CCA), but acquired resistance has been frequently observed in CCA patients. To search for potential long noncoding RNAs (lncRNAs) involved in gemcitabine resistance, two gemcitabine ...
Min Lu, Xinglei Qin, Yajun Zhou, Gang Li, Zhaoyang Liu, Xiwen Geng, Haodi Yue   +6 more
doaj   +1 more source

microRNA‐99a‐5p induces cellular senescence in gemcitabine‐resistant bladder cancer by targeting SMARCD1

Molecular Oncology, 2022
Patients with advanced bladder cancer are generally treated with a combination of chemotherapeutics, including gemcitabine, but the effect is limited due to acquisition of drug resistance. Thus, in this study, we investigated the mechanism of gemcitabine
Motoki Tamai, Shuichi Tatarano, Shunsuke Okamura, Wataru Fukumoto, Issei Kawakami, Yoichi Osako, Takashi Sakaguchi, Satoshi Sugita, Masaya Yonemori, Yasutoshi Yamada, Masayuki Nakagawa, Hideki Enokida, Hirofumi Yoshino   +12 more
doaj   +1 more source

PROM2 promotes gemcitabine chemoresistance via activating the Akt signaling pathway in pancreatic cancer

Experimental and Molecular Medicine, 2020
Pancreatic cancer: Exploring a pathway to drug resistance A cell membrane protein called PROM2 promotes the resistance of pancreatic cancer to the anti-cancer drug gemcitabine, suggesting PROM2 and the molecular signaling pathway it stimulates could be ...
Wenbin Li, Yue Zhu, Kelin Zhang, Xianhuan Yu, Haoming Lin, Wenrui Wu, Yaorong Peng, Jian Sun   +7 more
doaj   +1 more source

Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway. [PDF]

PLoS ONE, 2016
Gemcitabine-based chemotherapy remains one of the standards in management of metastatic breast cancer. However, intrinsic and acquired resistance to gemcitabine inevitably occurs.
Zhen-Hua Wu, Chen Lin, Ming-Ming Liu, Jian Zhang, Zhong-Hua Tao, Xi-Chun Hu   +5 more
doaj   +1 more source

Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer. [PDF]

, 2014
BackgroundPancreatic ductal adenocarcinoma has proven to be one of the most chemo-resistant among all solid organ malignancies. Several mechanisms of resistance have been described, though few reports of strategies to overcome this chemo-resistance have ...
Bold, Richard J, Daylami, Rouzbeh, Muilenburg, Diego J, Virudachalam, Subbulakshmi   +3 more
core   +2 more sources

Challenges of drug resistance in the management of pancreatic cancer [PDF]

, 2010
The current treatment of choice for metastatic pancreatic cancer involves single agent gemcitabine or combination of gemcitabine with capecitabine and erlotinib (tyrosine kinase inhibitor).
Akada, Allison, Almoguera, Andreetta, Arai, Arlt, Arteaga, Arumugam, Asano, Bachem, Baldwin, Banerjee, Bartsch, Bergers, Best, Bold, Bondar, Buck, Burris, Chakravarti, Chakravarti, Choi, Cunningham, Cunningham, Dancer, Dong, Duxbury, Duxbury, Duxbury, Duxbury, Engelman, Feldmann, Ferrero, Galmarini, Geyer, Giovannetti, Goan, Greer, Hagmann, Hahn, Henke, Hruban, Humeniuk, Ischenko, Ishikawa, Itoi, Jansen, Karapetis, Kindler, Kong, Koopman, Kulik, Lei, Lemoine, Liau, Liau, Longley, Mackey, Mackey, Mackey, Mahon, Mamaghani, Marechal, Marmor, Martin Clynes, Mata, Maxwell, Mendelsohn, Meropol, Miwa, Moertel, Molina-Arcas, Moore, Morgillo, Moriyama, Muerkoster, Muerkoster, Nakahira, Nakajima, Nakano, Naomi Walsh, Nishimura, Oguri, Okamoto, Okumura, Olive, O’Driscoll, Pao, Park, Park, Peters, Plunkett, Ray McDermott, Ritzel, Rizwan Sheikh, Robert O’Connor, Ruggeri, Safran, Saito, Sakamoto, Schuller, Sebastiani, Shah, Shi, Simon, Spratlin, Takao, Takebayashi, Treat, Tsukamoto, Tzeng, Vaishampayan, Van Cutsem, van der Wilt, Wang, Wang, Wang, Xiong, Yamasaki, Yokoi   +119 more
core   +1 more source

DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells. [PDF]

PLoS ONE, 2012
BACKGROUND: Down regulation of genes coding for nucleoside transporters and drug metabolism responsible for uptake and metabolic activation of the nucleoside gemcitabine is related with acquired tumor resistance against this agent.
Myrna Candelaria, Erick de la Cruz-Hernandez, Lucia Taja-Chayeb, Enrique Perez-Cardenas, Catalina Trejo-Becerril, Aurora Gonzalez-Fierro, Alma Chavez-Blanco, Ernesto Soto-Reyes, Guadalupe Dominguez, Jaenai E Trujillo, Jose Diaz-Chavez, Alfonso Duenas-Gonzalez   +11 more
doaj   +1 more source

Possible Role of Cytochrome P450 1B1 in the Mechanism of Gemcitabine Resistance in Pancreatic Cancer

Biomedicines, 2021
Patient-derived xenograft models reportedly represent original tumor morphology and gene mutation profiles. In addition, patient-derived xenografts are expected to recapitulate the parental tumor drug responses.
Erica Yada, Rika Kasajima, Atsushi Niida, Seiya Imoto, Satoru Miyano, Yohei Miyagi, Tetsuro Sasada, Satoshi Wada   +7 more
doaj   +1 more source

Reversible epigenetic regulation of 14-3-3σ expression in acquired gemcitabine resistance by uhrf1 and DNA methyltransferase 1 [PDF]

, 2014
Although gemcitabine is the most commonly used drug for treating pancreatic cancers, acquired gemcitabine resistance in a substantial number of patients appears to hinder its effectiveness in successful treatment of this dreadful disease.
Dong, Zizheng, Qin, Li, Zhang, Jian-Ting
core   +1 more source